Contacts

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued two patents, including U.S. Patent No. 11172829 (the ‘829 patent) titled “Thermoacoustic Transducer With Integrated Switch,” and U.S. Patent No. 11176848 (the ‘848 patent) titled “Tissue-mimicking Material for A Multi-modality Imaging Phantom.”

  • The ‘829 patent relates to a novel system for reducing false signals in thermoacoustic imaging. This patent enables mitigation of radiofrequency energy effects upon the electronic components of the system. ENDRA expects the ‘829 patent to be effective for all thermoacoustic imaging applications.
  • The ‘848 patent relates to ENDRA’s novel phantom for use with different imaging modalities including thermoacoustic imaging, ultrasound imaging and MRI. This patent enables health practitioners to use a single phantom instead of multiple phantoms when calibrating or validating a thermoacoustic system for use. The ‘848 patent should be particularly valuable as ENDRA proceeds with clinical trials in multiple countries.

“These issued patents – our 22nd and 23rd in the U.S. – support our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS® technology in areas with unmet clinical needs," stated ENDRA's Chief Executive Officer Francois Michelon. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently stands at 89 assets, which we define as patents issued, filed or in preparation.”

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements for ENDRA include, among others, estimates of the timing of future events and achievements, such as the expectations regarding the transition of leadership of ENDRA’s finance function, and expectations concerning ENDRA's business strategy, which may be affected by risks related to the impact of COVID-19 on its business plan, its ability to find and maintain development partners, market acceptance of its technology and the amount and nature of competition in its industry, its ability to protect its intellectual property, and other risks and uncertainties described in its filings with the Securities and Exchange Commission. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.